ArticleAging2021

Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.

Wenjing Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.